Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06602258
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-16
Brief Title:
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimers Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Placebo-Controlled Double-Blind Parallel-Group Dose-Finding Study to Evaluate Safety Tolerability and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimers Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to determine the dose response of E2814 when concurrently administered with lecanemab on the change from baseline at 6 months in cerebrospinal fluid CSF microtubule-binding region MTBR-tau-243 in participants with early Alzheimers disease AD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None